US2008131443A1PendingUtilityA1

Method and composition for reconforming multi-epitopic antigens to intiate an immune response

65
Assignee: ALTAREX MEDICAL CORPPriority: May 15, 1996Filed: Oct 31, 2007Published: Jun 5, 2008
Est. expiryMay 15, 2016(expired)· nominal 20-yr term from priority
C07K 2317/76C07K 2317/622A61K 2039/505A61P 37/04C07K 16/303C07K 2317/55C07K 16/4266C07K 16/3069A61P 35/00A61K 39/39558C07K 2317/732C07K 2317/734A61K 39/00
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention concerns methods and compositions for initiating and/or enhancing an immune response by contacting a binding reagent with a soluble antigen, wherein the binding reagent-antigen pair generates an immune response to the antigen.

Claims

exact text as granted — not AI-modified
1 . A method for treating cancer comprising
 contacting a multi-epitopic tumor-associated antigen expressed in the host serum with a composition comprising a binding reagent that specifically binds to a single epitope on the tumor-associated antigen; and   allowing the binding reagent to bind to the antigen to form a reagent-antigen pair, whereby the formation of the reagent-antigen pair elicits a host immune response.   
     
     
         2 . The method of  claim 1  wherein the binding reagent comprises a monoclonal antibody. 
     
     
         3 . The method of  claim 2  wherein the target multi-epitopic tumor associated antigen is CA 125. 
     
     
         4 . The method of  claim 2  wherein the target multi-epitopic tumor associated antigen is CA 19.9. 
     
     
         5 . The method of  claim 2  wherein the target multi-epitopic tumor associated antigen is CA 15.3. 
     
     
         6 . The method of  claim 1  wherein the tumor-associated antigen is an ovarian tumor antigen. 
     
     
         7 . The method of  claim 1  wherein the host immune response is a cellular immune response. 
     
     
         8 . The method of  claim 1  wherein the host immune response is a humoral immune response. 
     
     
         9 . The method of  claim 1  wherein the host immune response is both a humoral immune response and a cellular response. 
     
     
         10 . A method for eliciting an immune response comprising
 contacting a multi-epitopic tumor-associated antigen expressed in the host serum with a composition comprising a binding reagent that specifically binds to a single epitope on the tumor-associated antigen; and   allowing the binding reagent to bind to the antigen to form a reagent-antigen pair, whereby the formation of the reagent-antigen pair elicits a host immune response.   
     
     
         11 . A method for increasing the immunogenicity of an antigen comprising
 contacting a multi-epitopic tumor-associated antigen expressed in the host serum with a composition comprising a binding reagent that specifically binds to a single epitope on the tumor-associated antigen; and   allowing the binding reagent to bind to the antigen to form a reagent-antigen pair, whereby the formation of the reagent-antigen pair elicits a host immune response.   
     
     
         12 . A method for re-conforming a multi-epitopic tumor associated antigen expressed in a host serum and for recognizing and initiating an immune response, comprising contacting a multi-epitopic tumor-associated antigen expressed in the host serum with a composition comprising a binding reagent that specifically binds to a single epitope on the tumor-associated antigen; and
 allowing the binding reagent to bind to the antigen to form a reagent-antigen pair, whereby the formation of the reagent-antigen pair elicits a host immune response.   
     
     
         13 . A delivery system for a multi-epitopic tumor associated antigen expressed in a host serum, and for recognizing and initiating an immune response, comprising a composition comprising a binding reagent that specifically binds to a single epitope on a multi-epitopic tumor-associated antigen. 
     
     
         14 . The method of  claim 1  wherein the formation of the reagent-antigen pair elicits a host immune response that overcomes tolerance of the antigen. 
     
     
         15 . The method of  claim 1  wherein the contacting step is ex vivo or in vivo.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.